1. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
- Author
-
Cai, Sheng F., primary, Huang, Ying, additional, Lance, Jennie R., additional, Mao, Hsiaoyin Charlene, additional, Dunbar, Andrew J., additional, McNulty, Samantha N., additional, Druley, Todd, additional, Li, Yan, additional, Baer, Maria R., additional, Stock, Wendy, additional, Kovacsovics, Tibor, additional, Blum, William G., additional, Schiller, Gary J., additional, Olin, Rebecca L., additional, Foran, James M., additional, Litzow, Mark, additional, Lin, Tara, additional, Patel, Prapti, additional, Foster, Matthew C., additional, Boyiadzis, Michael, additional, Collins, Robert H., additional, Chervin, Jordan, additional, Shoben, Abigail, additional, Vergilio, Jo-Anne, additional, Heerema, Nyla A., additional, Rosenberg, Leonard, additional, Chen, Timothy L., additional, Yocum, Ashley O., additional, Druggan, Franchesca, additional, Marcus, Sonja, additional, Stefanos, Mona, additional, Druker, Brian J., additional, Mims, Alice S., additional, Borate, Uma, additional, Burd, Amy, additional, Byrd, John C., additional, Levine, Ross L., additional, and Stein, Eytan M., additional
- Published
- 2024
- Full Text
- View/download PDF